All In Biotech

Drug Trial Radar · NCT01657604

TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study

Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy

Last checked: Nov 19, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 717 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

717

Actual

Start

Aug 24, 2012

Primary completion

May 31, 2022

Study completion May 31, 2022

Sponsor

Lead sponsor
University of JenaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Advances in Chronic Myeloid Leukemia (CML) therapy led to an expected survival prolongation of \> 20 years after diagnosis. So far, discontinuation of tyrosine kinase inhibitors led to recurrence of disease in the majority of patients. The trial aims to improve treatment strategies in CML by improving induction therapy and deescalating maintenance therapy using low dose IFN as inducer of immunosurveillance. The trial will provide important data on the duration of active therapy in CML patients. Considering the rapidly increasing prevalence of CML this is of individual but also socioeconomic importance.

Conditions

  • Chronic Myeloid Leukemia

Interventions

  • Peginterferon α2bDrug

    Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.

  • NilotinibDrug

    Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MMR rate at 18 months of nilotinib monotherapy versus nilotinib+pegylated interferon alphaTime frame: at least 18 months after start of study treatment
  2. rate of continuous MMR after discontinuation of nilotinib versus pegylated interferon alphaTime frame: at least 12 months after stopping all therapy

Locations

112 sites in 3 countries. Site status is shown where the registry gives one.

  • University Hospital and Masaryk University Brno

    Brno, Czechia

  • Universitätsklinikum Aachen Medizinische Klinik IV

    Aachen, Germany

  • Gesundheitszentrum St. Marien GmbH, Onkologie/ Hämatologie Onkologisches Zentrum

    Amberg, Germany

  • MVZ am Klinikum Arnsberg GmbH, Hämatologie - Internistische Onkologie

    Arnsberg, Germany

  • Studienzentrum Drs. Klausmann

    Aschaffenburg, Germany

  • Klinikum Augsburg

    Augsburg, Germany

  • Klinikum Bayreuth GmbH

    Bayreuth, Germany

  • Vivantes Netzwerk für Gesundheit GmbH, Klinikum Neukölln, Klinik für Innere Medizin - Hämatologie und Onkologie

    Berlin, Germany

  • Charité CVK, CC14, Klinik für Hämatologie und Onkologie

    Berlin, Germany

  • Evangelisches Klinikum Bethel

    Bielefeld, Germany

  • Universitätsklinikum Bonn Med. Klinik und Poliklinik III, Hämatologie

    Bonn, Germany

  • Zentrum für Ambulante Hämatologie und Onkologie

    Bonn, Germany

  • Städtisches Klinikum Braunschweig gGmbh, Medizinische Klinik III - Hämatologie

    Braunschweig, Germany

  • Klinikum Bremen-Mitte gGmbH

    Bremen, Germany

  • DIAKO Ev. Diakonie-Krankenhaus gGmbH, Medizinische Klinik II

    Bremen, Germany

  • Klinikum Chemnitz gGmbH Klinik für Innere Medizin III

    Chemnitz, Germany

  • Universitätsklinikum Köln

    Cologne, Germany

  • Onkologische Schwerpunktpraxis

    Dresden, Germany

  • Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

    Dresden, Germany

  • Onkologisch-Hämatologische Schwerpunktpraxis

    Eisenach, Germany

  • Dr. med. Ulrich Hauch

    Erfurt, Germany

  • Onkologische Schwerpunktpraxis Erlangen, Onkologie, Hämatologie

    Erlangen, Germany

  • Universitätsklinikum Erlangen Medizinische Klinik 5 - Hämatologie und int. Onkologie

    Erlangen, Germany

  • St.-Antonius-Hospital, Klinik für Hämatologie Onkologie

    Eschweiler, Germany

  • Klinik für Hämatologie Universitätsklinikum Essen

    Essen, Germany

  • Klinikum der Goethe Universität

    Frankfurt, Germany

  • Universitätsklinikum Freiburg Abteilung Innere Medizin I - Hämatologie und Onkologie

    Freiburg im Breisgau, Germany

  • MVZ-Osthessen GmbH Klinikum Fulda Tumorklinik

    Fulda, Germany

  • Praxis Dr. med. Schmitt

    Gerlingen, Germany

  • Dr. med. Hans Werner Tessen, Facharzt für Innere Medizin

    Goslar, Germany

  • Georg-August Universität Göttingen Abteilung Hämatologie und Onkologie

    Göttingen, Germany

  • Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere

    Greifswald, Germany

  • Internistische Gemeinschaftspraxis

    Güstrow, Germany

  • Katholisches Krankenhaus Hagen gem. GmbH, Klinik für Hämatologie und

    Hagen, Germany

  • Gemeinschaftspraxis Hämatologie und internistische

    Halle, Germany

  • Universitätsklinikum Halle (Saale)

    Halle, Germany

  • Asklepios Klinik St. Georg, Abteilung Hämatologie, Onkologie, Stammzelltransplantation

    Hamburg, Germany

  • Universitätsklinikum Hamburg- Eppendorf, Medizinische Klinik 2

    Hamburg, Germany

  • Evangelisches Krankenhaus Hamm

    Hamm, Germany

  • St. Barbara-Klinik, Standort St. Josef

    Hamm, Germany

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.